HKHugh Kearney

Hugh Kearney

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hugh Kearney has a total of 196 co-authors. Here are the top co-authors by number of shared publications:

  • Alan Beausang

    Department of Neuropathology Beaumont Hospital Dublin Ireland

    5 shared publications
  • Jane Cryan

    Department of Neuropathology Beaumont Hospital Dublin Ireland

    4 shared publications
  • Olga Ciccarelli

    NMR Research Unit, Queen Square MS Centre, UCL Institute of Neurology, UK/NIHR University College London Hospitals Biomedical Research Centre, UK

    4 shared publications
  • Claudia Angewla Michela Gandini Wheeler-Kingshott

    Department of Brain and Behavioral Sciences, University of Pavia

    3 shared publications
  • David H. Miller

    From the NMR Research Unit (H.K., D.R.A., R.S.S., M.C.Y., C.A.M.W.-K., O.C., D.H.M.), Queen Square MS Centre, UCL Institute of Neurology, London; the Department of Medical Statistics (D.R.A.), London School of Hygiene and Tropical Medicine; and NIHR University College London Hospitals Biomedical Research Centre (C.A.M.W.-K., O.C., D.H.M.), UK

    3 shared publications
  • Francesca Brett

    Department of Neuropathology Beaumont Hospital Dublin Ireland

    3 shared publications

Latest Publications

  • Open Access

    Neurologists’ perspectives of cannabis-based medicines: results from an all-Ireland survey

    by Michael Savio, Hugh Kearney, Eric J. Downer

    Background: Advancements continue to be made in the development of medicines containing components of the Cannabis sativa L. plant. Consultants can prescribe specific cannabis-based products for a restricted set of indications in Ireland, with neurologists being at the forefront of therapy. Much debate on the therapeutic potential/efficacy of such cannabis-based products exists. Aim: The objective of this study was to conduct a national survey to determine the perspectives/views of Irish neurologists regarding the use of cannabis-based medicines. Methods: An online anonymous survey was conducted to capture the perspectives and experiences of neurologists in Ireland regarding cannabis-based therapeutics. Results: Thirty-four neurologists completed the survey in full, with study participants rating their knowledge of cannabis-based medicines as average. Data presented herein indicate that there is a need for educational programmes on the cannabinoid system and cannabinoid-based medicines, and the findings indicate that neurologists are interested in the use of cannabinoid-based medicines in their practice. Study participants were more divided with regard to the clarity of the process for accessing cannabis-based medicines, and the consensus is that the application process is unclear. Approximately one-third of participants have made an application to access medicinal cannabis-based products on behalf of a patient. Conclusions: Data presented herein indicates that the majority of neurologists surveyed are aware of the current systems in place to access cannabis-based products for medicinal use in Ireland and that some engagement with these systems has taken place. A key finding is that educational programmes on the cannabinoid system and cannabis-based medicines are required.


  • Open Access

    Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides

    by Lara Dungan, Jean Dunne, Michael Savio, Marianna Kalaszi, Matt McElheron, Yvonne Lynagh, Kate O'DRiscoll, Carmel Roche, Ammara Qureshi, Brendan Crowley, et al.

    Background and ObjectivesEpstein-Barr virus (EBV) has been strongly implicated in the pathogenesis of multiple sclerosis (MS). Despite this, there are no routinely used tests to measure cellular response to EBV. In this study, we analyzed the cellular ...


  • Open Access

    Somatic variants as a cause of drug‐resistant epilepsy including mesial temporal lobe epilepsy with hippocampal sclerosis

    by Robert J. Carton, Michael G. Doyle, Hugh Kearney, Charles A. Steward, Nicholas J. Lench, Anthony Rogers, Erin L. Heinzen, Seamus McDonald, Joanna Fay, Austin Lacey, et al.

    Objective: The contribution of somatic variants to epilepsy has recently been demonstrated, particularly in the etiology of malformations of cortical development. The aim of this study was to determine the diagnostic yield of somatic variants in genes that have been previously associated with a somatic or germline epilepsy model, ascertained from resected brain tissue from patients with multidrug‐resistant focal epilepsy.Methods: Forty‐two patients were recruited across three categories: (1) malformations of cortical development, (2) mesial temporal lobe epilepsy with hippocampal sclerosis, and (3) nonlesional focal epilepsy. Participants were subdivided based on histopathology of the resected brain. Paired blood‐ and brain‐derived DNA samples were sequenced using high‐coverage targeted next generation sequencing to high depth (585× and 1360×, respectively). Variants were identified using Genome Analysis ToolKit (GATK4) MuTect‐2 and confirmed using high‐coverage Amplicon‐EZ sequencing.Results: Sequence data on 41 patients passed quality control. Four somatic variants were validated following amplicon sequencing: within CBL, ALG13, MTOR, and FLNA. The diagnostic yield across 41 patients was 10%, 9% in mesial temporal lobe epilepsy with hippocampal sclerosis and 20% in malformations of cortical development.Significance: This study provides novel insights into the etiology of mesial temporal lobe epilepsy with hippocampal sclerosis, highlighting a potential pathogenic role of somatic variants in CBL and ALG13. We also report candidate diagnostic somatic variants in FLNA in focal cortical dysplasia, while providing further insight into the importance of MTOR and related genes in focal cortical dysplasia. This work demonstrates the potential molecular diagnostic value of variants in both germline and somatic epilepsy genes.


  • Open Access

    Everolimus precision therapy for the GATOR1‐related epilepsies: A case series

    by Patrick B. Moloney, Hugh Kearney, Katherine A. Benson, Daniel J. Costello, Gianpiero L. Cavalleri, Kathleen M. Gorman, Bryan J. Lynch, Norman Delanty

    Background: Pathogenic variants in the GAP activity towards RAGs 1 (GATOR1) complex genes (DEPDC5, NPRL2, NPRL3) cause focal epilepsy through hyperactivation of the mechanistic target of rapamycin pathway. We report our experience using everolimus in patients with refractory GATOR1‐related epilepsy.Methods: We performed an open‐label observational study of everolimus for drug‐resistant epilepsy caused by variants in DEPDC5, NPRL2 and NPRL3. Everolimus was titrated to a target serum concentration (5–15 ng/mL). The primary outcome measure was change in mean monthly seizure frequency compared with baseline.Results: Five patients were treated with everolimus. All had highly active (median baseline seizure frequency, 18/month) and refractory focal epilepsy (failed 5–16 prior anti‐seizure medications). Four had DEPDC5 variants (three loss‐of‐function, one missense) and one had a NPRL3 splice‐site variant. All patients with DEPDC5 loss‐of‐function variants had significantly reduced seizures (74.3%–86.1%), although one stopped everolimus after 12 months due to psychiatric symptoms. Everolimus was less effective in the patient with a DEPDC5 missense variant (43.9% seizure frequency reduction). The patient with NPRL3‐related epilepsy had seizure worsening. The most common adverse event was stomatitis.Conclusions: Our study provides the first human data on the potential benefit of everolimus precision therapy for epilepsy caused by DEPDC5 loss‐of‐function variants. Further studies are needed to support our findings.


  • Open Access

    Neuropathologically informed imaging of cortical grey matter lesions in MS – A pilot study

    by S Quigley, M.C. Yiannakas, P. Bede, J. Meaney, H. Kearney

  • Open Access

    Spectrum of Phenotypic, Genetic, and Functional Characteristics in Patients With Epilepsy With KCNC2 Pathogenic Variants

    by Niklas Schwarz, Simone Seiffert, Manuela Pendziwiat, Annika Verena Rademacher, Tobias Brünger, Ulrike B.S. Hedrich, Paul B. Augustijn, Hartmut Baier, Allan Bayat, Francesca Bisulli, et al.

    Background and Objectives KCNC2 encodes Kv3.2, a member of the Shaw-related (Kv3) voltage-gated potassium channel subfamily, which is important for sustained high-frequency firing and optimized energy efficiency of action potentials in the brain. The objective of this study was to analyze the clinical phenotype, genetic background, and biophysical function of disease-associated Kv3.2 variants. Methods Individuals with KCNC2 variants detected by exome sequencing were selected for clinical, further genetic, and functional analysis. Cases were referred through clinical and research collaborations. Selected de novo variants were examined electrophysiologically in Xenopus laevis oocytes. Results We identified novel KCNC2 variants in 18 patients with various forms of epilepsy, including genetic generalized epilepsy (GGE), developmental and epileptic encephalopathy (DEE) including early-onset absence epilepsy, focal epilepsy, and myoclonic-atonic epilepsy. Of the 18 variants, 10 were de novo and 8 were classified as modifying variants. Eight drug-responsive patients became seizure-free using valproic acid as monotherapy or in combination, including severe DEE cases. Functional analysis of 4 variants demonstrated gain of function in 3 severely affected DEE cases and loss of function in 1 case with a milder phenotype (GGE) as the underlying pathomechanisms. Discussion These findings implicate KCNC2 as a novel causative gene for epilepsy and emphasize the critical role of KV3.2 in the regulation of brain excitability.


  • Postural stability is a valid and meaningful disability metric in progressive MS with potential for use in neuroprotective therapy trials

    by Siew Mei Yap, Mark S. Etzelmueller, Clodagh O'KEeffe, Maria Gaughan, Hugh Kearney, Niall Tubridy, Richard B. Reilly, Christopher McGuigan


  • Open Access

    Modeling seizures in the Human Phenotype Ontology according to contemporary ILAE concepts makes big phenotypic data tractable

    by David Lewis‐Smith, Peter D. Galer, Ganna Balagura, Hugh Kearney, Shiva Ganesan, Mahgenn Cosico, Margaret O'BRien, Priya Vaidiswaran, Roland Krause, Colin A. Ellis, et al.

    Objective: The clinical features of epilepsy determine how it is defined, which in turn guides management. Therefore, consideration of the fundamental clinical entities that comprise an epilepsy is essential in the study of causes, trajectories, and treatment responses. The Human Phenotype Ontology (HPO) is used widely in clinical and research genetics for concise communication and modeling of clinical features, allowing extracted data to be harmonized using logical inference. We sought to redesign the HPO seizure subontology to improve its consistency with current epileptological concepts, supporting the use of large clinical data sets in high‐throughput clinical and research genomics.Methods: We created a new HPO seizure subontology based on the 2017 International League Against Epilepsy (ILAE) Operational Classification of Seizure Types, and integrated concepts of status epilepticus, febrile, reflex, and neonatal seizures at different levels of detail. We compared the HPO seizure subontology prior to, and following, our revision, according to the information that could be inferred about the seizures of 791 individuals from three independent cohorts: 2 previously published and 150 newly recruited individuals. Each cohort's data were provided in a different format and harmonized using the two versions of the HPO.Results: The new seizure subontology increased the number of descriptive concepts for seizures 5‐fold. The number of seizure descriptors that could be annotated to the cohort increased by 40% and the total amount of information about individuals' seizures increased by 38%. The most important qualitative difference was the relationship of focal to bilateral tonic‐clonic seizure to generalized‐onset and focal‐onset seizures.Significance: We have generated a detailed contemporary conceptual map for harmonization of clinical seizure data, implemented in the official 2020‐12‐07 HPO release and freely available at hpo.jax.org. This will help to overcome the phenotypic bottleneck in genomics, facilitate reuse of valuable data, and ultimately improve diagnostics and precision treatment of the epilepsies.


  • Coproducing health and well-being in partnership with patients, families, and healthcare providers: A qualitative study exploring the role of an epilepsy patient portal

    by Zita McCrea, Kevin Power, Rachel Kiersey, Maire White, Annette Breen, Sinead Murphy, Laura Healy, Hugh Kearney, Brendan Dunleavy, Sean O'DOnoghue, et al.